Category Archives: Clinical Cardiology

The American College of Cardiology (ACC) has released a new Expert Consensus Decision Pathway (ECDP) on the use of anticoagulant and antiplatelet therapy in patients with atrial fibrillation (AF) or venous thromboembolism (VTE) undergoing percutaneous coronary intervention (PCI). "Its estimated that about 10%-15% of patients undergoing PCI have concomitant AF or VTE and need both anticoagulants and antiplatelets, so this is a very common clinical scenario," said committee chair Dharam J Continue reading →

In fact, the ACC guidelines include a recommendation against the use of triple antithrombotictherapy for most patients and urges physicians to consider dual antithrombotictherapy consisting of an anticoagulant and a P2Y12 inhibitor when patients require both an anticoagulant and antiplatelet therapy following percutaneous coronary intervention (PCI). Much of the guidance focusses on four clinical scenarios: This is a complex topic, and we have attempted to cite the literature to offer direct guidance when possible and to highlight areas in which clinical judgement is needed, wrote writing committee chair Dharam J. Continue reading →

Thanks to celebrity fans like Gwyneth Paltrow, Lady Gaga, and Jennifer Anniston, infrared saunas have become one of the hottest wellness accessories in recent years. The Instagrammable wooden saunas, which get cranked up to around 60 degrees celsius, come with a laundry list of benefits, but theres just one problem: you can only access them at swanky urban spas, or if you have the money and space to install one in your home. Continue reading →

At the end of March, George Hripcsak, MD, had expected to attend a symposium in England for a global interdisciplinary research collaborative whose coordinating center operates out of VP&S. Instead, on March 26, Hripcsak and fellow members of the leadership committee of the Observational Health Data Sciences and Informatics (or OHDSI, pronounced Odyssey) launched an 88-hour virtual study-a-thon with more than 300 investigators from dozens of countries in attendance. This is how we shifted our efforts to COVID, says Hripcsak, co-PI of the international OHDSI, an around-the-clock, four-day meeting of researchers from North America, Europe, and Asia, coming together to kick off our COVID study. Continue reading →

Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Two Late Breaker and Six e-Poster Presentations, Including Encore of REDUCE-IT EPA, Primary Results of the VASCEPA COVID-19 CardioLink-9 Trial, and Mechanism of Action Insights DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that scientific findings that add to the growing body of knowledge on VASCEPA (icosapent ethyl) will be presented during the National Lipid Association (NLA) Scientific Sessions 2020, being held virtually from December 10 12, 2020 Continue reading →

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Tuesday, December 15, 2020 at 11:00am ET to discuss GB002, its inhaled PDGFR inhibitor, for the treatment of pulmonary arterial hypertension (PAH) Continue reading →

A study conducted by UAB investigators has outlined that deaths due to mitral regurgitation are increasing in the United States since 2012, after a continuous decline for 14 years. Continue reading →

A novel tool in which clinical risk factors and coronary artery calcium score (CACS) are added to standard pre-test probability (PTP) modeling was found to improve risk prediction in suspected obstructive coronary artery disease (CAD), according to a study published in the Journal of the American College of Cardiology. Continue reading →

Inflammatory bowel disease (IBD) has thus far been overlooked as a contributor to atherosclerotic cardiovascular disease (ASCVD) risk, urges a new review that outlines whats known about the overlap between the two and offers advice on next steps. While the inflammatory hypothesis for cardiovascular disease has recently gained tractionwhat with positive results from CANTOS, COLCOT, and LoDoCo2data specific to IBD are scarce, authors say Continue reading →

4DMT has made tremendous progress since the close of our Series C financing. We have advanced product candidates across our key therapeutic areas of ophthalmology, cardiology and pulmonology, including the initiation of the clinical programs for 4D-110 and 4D-125 in ophthalmology, and 4D-310 for the treatment of Fabry disease, said David Kirn, M.D., co-founder and chief executive officer of 4DMT. With the addition of Robert Fishman, Raphael Schiffmann and Robert Kim to our clinical R&D leadership team, 4DMT gains not only extensive experience in clinical development and translational medicine, but also unique and specific experience within each of the initial 4DMT therapeutic areas. Continue reading →